



National Institute of
Neurological Disorders
and Stroke

INNOVATION GRANTS TO NURTURE INITIAL TRANSLATIONAL EFFORTS (IGNITE)

Division of Translational Research



Visit the *IGNITE*
website

A Suite Of Early-Stage Translational Funding Opportunities

Overall Goal:

- Encourage the translation of research discoveries into new neurotherapeutics
- Advance projects to meet entry criteria for other NINDS translational programs (ex. BPN)

Entry Criteria


- Strong biological rationale
- Relevance for therapy development



Budget: ≤ \$499,000/Year; ≤ \$750,000 for the 3-year project


The R61/R33 Mechanism

R61: Demonstrate Feasibility and
Prepare for R33 (≤ 2 years)



Go/No-Go Milestones
Does this warrant
further effort?

R33: The Main Event
(≤ 2 years)



➤ Clear, quantitative and definitive milestones are essential

PAR-21-122

Neurotherapeutic
Characterization
and In vivo
Efficacy Studies

Goal: Demonstrate proof of concept for early
therapeutic using the following parameters:

- Physiochemical/Biochemical characteristics
- Target engagement/PD studies
- Pharmacokinetic (PK) studies
- In vivo efficacy

PAR-21-123

Development &
Validation of
Model Systems

Goals: Improve translational preclinical models used
for the neurotherapeutic discovery/development
process

- Animal models
- Human/tissue ex vivo



PAR-21-124

Assay Development
& Neurotherapeutic
Agent Identification

Goals: Develop primary and secondary screening
assays & Conduct screening efforts to identify and
characterize potential neurotherapeutic agents.

Additional Entry Criteria: Available test agent(s) or
library



**Next Application
due date:**

October 21, 2024

Program Director:
Dr. Becky Roof,
Rebecca.roof@nih.gov